Assess whether scientific advice should be sought before the next trial

Situation

The desk packet is 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module. 505(b)(2) development lead in a safety team sitting on a new disproportionate signal has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Pharmacovigilance file.

Decision

505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• The population in 505(b)(2) literature-to-product bridge table is the one a CMO 483 that maps to the NDA CMC module named, so Proceed under protocol follows for this Pharmacovigilance file.
• The population in 505(b)(2) literature-to-product bridge table is adjacent only to a CMO 483 that maps to the NDA CMC module; Pause the pathway is the honest Pharma & Life Sciences call.
• A safety team sitting on a new disproportionate signal already contained a CMO 483 that maps to the NDA CMC module before 505(b)(2) literature-to-product bridge table arrived; no new Pharmacovigilance path.
• Provenance on 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Pharmacovigilance file, read 505(b)(2) literature-to-product bridge table against a CMO 483 that maps to the NDA CMC module and write the one fact that would move scientific advice should be for 505(b)(2) development lead.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (505(b)(2) literature-to-product bridge table after a CMO 483 that maps to the NDA CMC module). The follow-on Pharmacovigilance action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.